| # | Drug | Count |
|---|---|---|
| 0 | QUETIAPINE | 803 |
| 1 | PEMBROLIZUMAB | 727 |
| 2 | NIVOLUMAB | 682 |
| 3 | OLANZAPINE | 420 |
| 4 | IPILIMUMAB | 368 |
| 5 | RISPERIDONE | 356 |
| 6 | OLANZAPINE PAMOATE | 341 |
| 7 | INSULIN GLARGINE | 285 |
| 8 | ARIPIPRAZOLE | 268 |
| 9 | PREDNISONE | 268 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ZIPRASIDONE | 139 | 0.0386 |
| 1 | ZIPRASIDONE MESYLATE | 137 | 0.0097 |
| 2 | IPILIMUMAB | 368 | 0.0084 |
| 3 | OLANZAPINE PAMOATE | 341 | 0.0084 |
| 4 | HALOPERIDOL DECANOATE | 13 | 0.0075 |
| 5 | NIVOLUMAB | 682 | 0.0070 |
| 6 | PEMBROLIZUMAB | 727 | 0.0067 |
| 7 | HUMAN INSULIN | 47 | 0.0066 |
| 8 | DOSTARLIMAB | 15 | 0.0060 |
| 9 | OLANZAPINE | 420 | 0.0060 |
| # | Drug class | Count |
|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 1554 |
| 1 | Atypical Antipsychotic [EPC] | 808 |
| 2 | Corticosteroid [EPC] | 574 |
| 3 | Insulin Analog [EPC] | 551 |
| 4 | Benzodiazepine [EPC] | 508 |
| 5 | Nonsteroidal Anti-inflammatory Drug [EPC] | 454 |
| 6 | CTLA-4-directed Blocking Antibody [EPC] | 379 |
| 7 | HMG-CoA Reductase Inhibitor [EPC] | 255 |
| 8 | Platinum-based Drug [EPC] | 241 |
| 9 | Proton Pump Inhibitor [EPC] | 237 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 1554 | 0.0158 |
| 1 | Interleukin-5 Antagonist [EPC] | 10 | 0.0145 |
| 2 | CTLA-4-directed Blocking Antibody [EPC] | 379 | 0.0079 |
| 3 | Leptin Analog [EPC] | 6 | 0.0048 |
| 4 | Provitamin D2 Compound [EPC] | 123 | 0.0041 |
| 5 | Insulin-like Growth Factor-1 Receptor Inhibitor [EPC] | 22 | 0.0037 |
| 6 | Sulfone [EPC] | 39 | 0.0036 |
| 7 | Programmed Death Ligand-1 Blocker [EPC] | 76 | 0.0035 |
| 8 | Antihypoglycemic Agent [EPC] | 13 | 0.0030 |
| 9 | Guanylate Cyclase-C Agonist [EPC] | 6 | 0.0029 |